Hyponatremia During Induction Therapy in Distinct Pediatric Oncological Cohorts: A Retrospective Study.
alkaloids
children
hyponatremia
leukemia
triglycerides
vincristine
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
05
2021
accepted:
30
09
2021
entrez:
15
11
2021
pubmed:
16
11
2021
medline:
16
11
2021
Statut:
epublish
Résumé
Hyponatremia is a well-known adverse event of repeated therapy with vincristine in oncological patients. However, to date, data in pediatric patients with malignant diseases other than acute lymphoblastic leukemia (ALL) are sparse or lacking. A retrospective study of 98 pediatric patients was conducted to analyze the incidence of hyponatremia in a Caucasian cohort of newly diagnosed ALL. For comparison, we further examined five other pediatric oncological cohorts (Hodgkin's disease, Ewing sarcoma, Wilms tumor, benign glioma of the CNS, Langerhans cell histiocytosis) that receive alkaloids in their induction regimes. We found a high incidence of hyponatremia (14.7%) in our ALL cohort with a trend toward male patients of elementary school age. None of the affected patients showed neurological symptoms. By comparison, patients from other malignancy groups did not show significant hyponatremia, regardless of their comparable therapy with alkaloids. We here show a noticeable coincidence of hyponatremia and hypertriglyceridemia in ALL patients, indicating a possible role of L-asparaginase-related hypertriglyceridemia in the development of severe hyponatremia in such patients. We report a higher incidence of hyponatremia following vincristine therapy in Caucasian children with ALL than published before. This hyponatremia could not be demonstrated in other oncologic cohorts treated with alkaloids. L-Asparaginase-induced hypertriglyceridemia may play a role in the certainly multifactorial development of hyponatremia in childhood leukemia.
Sections du résumé
BACKGROUND
BACKGROUND
Hyponatremia is a well-known adverse event of repeated therapy with vincristine in oncological patients. However, to date, data in pediatric patients with malignant diseases other than acute lymphoblastic leukemia (ALL) are sparse or lacking.
MATERIALS AND METHODS
METHODS
A retrospective study of 98 pediatric patients was conducted to analyze the incidence of hyponatremia in a Caucasian cohort of newly diagnosed ALL. For comparison, we further examined five other pediatric oncological cohorts (Hodgkin's disease, Ewing sarcoma, Wilms tumor, benign glioma of the CNS, Langerhans cell histiocytosis) that receive alkaloids in their induction regimes.
RESULTS
RESULTS
We found a high incidence of hyponatremia (14.7%) in our ALL cohort with a trend toward male patients of elementary school age. None of the affected patients showed neurological symptoms. By comparison, patients from other malignancy groups did not show significant hyponatremia, regardless of their comparable therapy with alkaloids. We here show a noticeable coincidence of hyponatremia and hypertriglyceridemia in ALL patients, indicating a possible role of L-asparaginase-related hypertriglyceridemia in the development of severe hyponatremia in such patients.
CONCLUSION
CONCLUSIONS
We report a higher incidence of hyponatremia following vincristine therapy in Caucasian children with ALL than published before. This hyponatremia could not be demonstrated in other oncologic cohorts treated with alkaloids. L-Asparaginase-induced hypertriglyceridemia may play a role in the certainly multifactorial development of hyponatremia in childhood leukemia.
Identifiants
pubmed: 34778028
doi: 10.3389/fonc.2021.708875
pmc: PMC8586428
doi:
Types de publication
Journal Article
Langues
eng
Pagination
708875Informations de copyright
Copyright © 2021 Salvador, Salvador, Willeit, Kuntner, Haid, Müller, Kropshofer and Crazzolara.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Med. 1957 Oct;23(4):529-42
pubmed: 13469824
J Pediatr. 1972 Jul;81(1):90-2
pubmed: 4338387
J Intern Med. 1995 Aug;238(2):97-110
pubmed: 7629492
Indian J Cancer. 2019 Oct-Dec;56(4):320-324
pubmed: 31607700
J Pediatr Hematol Oncol. 2002 Oct;24(7):591
pubmed: 12368705
J Pediatr. 2013 Dec;163(6):1646-51
pubmed: 23998517
Crit Rev Oncol Hematol. 2016 Jun;102:15-25
pubmed: 27066939
Neurochirurgie. 1972 Mar-Apr;18(2):137-41
pubmed: 5074919
Cochrane Database Syst Rev. 2014 Dec 18;(12):CD009457
pubmed: 25519949
Oncotarget. 2017 Dec 20;9(5):6595-6606
pubmed: 29464095
Am J Med. 1971 Aug;51(2):269-71
pubmed: 5095530
J Natl Cancer Inst. 1966 Sep;37(3):331-5
pubmed: 5951008
Int J Cancer. 2001 Feb 1;91(3):402-6
pubmed: 11169966
J Neurol. 1983;229(4):267-72
pubmed: 6192229
Cleve Clin J Med. 1992 Nov-Dec;59(6):643-4
pubmed: 1424076
J Assoc Physicians India. 2010 Aug;58:519-20
pubmed: 21192351
Pediatrics. 2018 Dec;142(6):
pubmed: 30478247
J Pediatr Hematol Oncol. 2017 Mar;39(2):e54-e58
pubmed: 28060134
N Engl J Med. 2015 Oct;373(14):1350-60
pubmed: 26422725
Med Oncol Tumor Pharmacother. 1988;5(1):67-9
pubmed: 2452936
Am J Ther. 2019 Nov/Dec;26(6):e722-e723
pubmed: 30418228
Mycoses. 2012 Jul;55(4):290-7
pubmed: 22126626
J Clin Pharm Ther. 2018 Feb;43(1):137-140
pubmed: 28782144
Support Care Cancer. 2007 Dec;15(12):1341-7
pubmed: 17701059
J Pediatr. 2014 Jul;165(1):163-169.e2
pubmed: 24582105
J Surg Oncol. 1983 Nov;24(3):242-5
pubmed: 6195486
Clin Chem. 2018 Feb;64(2):414-415
pubmed: 29378746
Electrolyte Blood Press. 2006 Nov;4(2):77-82
pubmed: 24459491
J Community Hosp Intern Med Perspect. 2016 Jul 06;6(3):31808
pubmed: 27406459
Support Care Cancer. 1996 Sep;4(5):341-50
pubmed: 8883227
Leuk Lymphoma. 2011 Dec;52(12):2237-53
pubmed: 21827361
Cancer. 1969 Jan;23(1):122-5
pubmed: 4974027
Indian J Crit Care Med. 2009 Jul-Sep;13(3):167-8
pubmed: 20040817
Blood. 1975 Mar;45(3):315-20
pubmed: 1054263
N Engl J Med. 1984 May 24;310(21):1353-6
pubmed: 6546971
J Intensive Care Med. 2018 Mar;33(3):147-158
pubmed: 28535742
Eur Endocrinol. 2020 Oct;16(2):122-130
pubmed: 33117443
Clin Lab Haematol. 1998 Apr;20(2):123-4
pubmed: 9681224
Arch Dis Child. 2020 Oct 28;:
pubmed: 33115710
Pediatr Blood Cancer. 2010 May;54(5):734-7
pubmed: 20205255
Ann Intern Med. 1974 Jun;80(6):733-7
pubmed: 4364934
Blood Rev. 2002 Dec;16(4):225-43
pubmed: 12350366
Am J Dis Child. 1966 Sep;112(3):256-9
pubmed: 5945540
J Clin Lipidol. 2018 Sep - Oct;12(5):1260-1266
pubmed: 30055974
Oncologist. 2012;17(6):756-65
pubmed: 22618570
Acta Paediatr. 2001 Oct;90(10):1204-7
pubmed: 11697438
Arch Intern Med. 1973 Nov;132(5):717-20
pubmed: 4356234
Am J Med. 1967 May;42(5):713-44
pubmed: 5337375